Shows
Back Bay Life Science ReportDynamics in Healthcare Focused MarketsIn this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They focus on key drivers affecting markets this year and discuss the recent news of the Fed’s decision to cut interest rates by 50-basis points. Topics in the podcast include: After two difficult years, the appearance of a healthy market rotation since July The Fed’s decision mid-September to cut rates by 50 basis points Healthcare IPOs: historical and recent a...2024-09-3020 min
Back Bay Life Science ReportKey Considerations for a US Healthcare IPOIn this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange. Topics in this podcast include: An overview of the decision-making process through execution for US-based and ex-US healthcare companies thinking about listing in the USCore considerations after deciding to pursue a US listing and how to prepare most effectivelyBuilding the “IPO advisory team”: types of advisors (legal, accounting, banking, IR firms, IP, etc.) and when to bring them inKey documents and associated timelines related to the S...2024-05-2235 min
Back Bay Life Science ReportThe Current Dynamics in Capital MarketsWelcome to another episode with the DNB//Back Bay Partnership for Healthcare.In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director of US Equity Capital Markets at DNB, and Vasilios Kofitsas, Managing Director of Investment Banking at Back Bay Life Science Advisors, to talk about current market dynamics and the 2024 IPO outlook in the US and in Europe.Topics in this podcast include:Trends, cycles and the current state of capital markets in Europe...2024-04-1522 min
Back Bay Life Science ReportThe Heart of the Matter: Behind the Renewed Interest in Cardiovascular DiseaseA conversation on the rising trends in the cardiology spaceCardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.Episode topics include: Why pharma’s interest in specialty-like approaches has shi...2023-10-1224 minBack Bay Life Science ReportContingencies for Biopharma, Medtech Deal Planning in a Down MarketFor biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting. In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more closely guarded and the competition becomes fierce. In this episode of Back Bay’s industry podcast, the Life Science Report, Jonatha...2023-02-0928 minBack Bay Life Science ReportPreparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq NordicFor biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And although the specific logistical and mechanical aspects are exceedingly important, at the end of the day, the decision to do something like this is predicated on an amalgam of strategic decisions. In this episode Back Bay Lif...2022-09-2028 minBack Bay Life Science ReportLife Science SPACs: A Forward Look at this Evolving Asset ClassWelcome to Episode #2 of The Life Science Report. In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs).The feeling surrounding healthcare SPACs right now is almost...giddy. With enormous capital flowing into the biotech sector, SPACs have emerged as one of the hottest financing options. Last year, the market saw $80B in SPAC issuance, which 2021 will far exceed.We’re still in the beginning of this...2021-06-0325 minBack Bay Life Science ReportGene Therapies: What’s to Come as The Industry Moves ForwardWelcome to Episode 1 of The Life Science Report. In this episode our host, Dr. Peter Bak, sits down with Brendan Wang and Kyle O’Neil of Back Bay Life Science Advisors to discuss the field of gene therapies and insights from their recently authored piece in Cell & Gene, “The Next Decade In Gene Therapy Innovation — 6 Critical Questions (And Answers),” and their newly released white paper on BBLSA.com.Gene therapy has been talked about for many years, and it’s only in the past few years that we’ve begun to see some initial products make it to market. W...2021-06-0221 min